Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders

HIV Clinical Trial

— Inspire 3  

Official title:

A Multicenter, Open-labeled, Controlled, Randomized Study of Recombinant Interleukin-7 (CYT107) Treatment to Restore and Maintain CD4 T-lymphocyte Counts Above 500 Cells/µL in HIV-infected Patients With CD4 Counts Remaining Between 101-350 Cells/µL After at Least 2 Years of HAART and Plasma HIV RNA < 50 Copies/mL for 18 Months.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01241643
• Other study ID #: CLI-107-14
• Status: Terminated
• Phase: Phase 2
• First received: November 15, 2010
• Last updated: July 24, 2013
• Start date: September 2010
• Est. completion date: June 2013

Study information

• Verified date: July 2013
• Source: Cytheris SA
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy : Fondazione Centro S. Raffale del Monte TaborSouth Africa : MCC
• Study type: Interventional

Clinical Trial Summary

This is a Phase II multicenter, open-labeled, controlled, randomized study assessing weekly doses of Interleukin-7 (CYT107)

Description:

The aim of the study is to assess repeated cycles of 3 weekly injections of CYT107 in patients immune non-responders infected with HIV.

Eighty patients will be recruited to study the biological activity and safety of repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months. The entire study will cover a period of 24 months.

During the study visits the following may be done:

• medical history, physical examination, blood test every visit

• EKG

• chest X-Ray

• liver/spleen ultrasound

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 92
• Est. completion date: June 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. HIV-1 infection as documented by any licensed ELISA (Enzyme-Linked Immunosorbent Assay) test kit and confirmed either by Western Blot or a 2nd test using a different method at any time prior to study entry

2. Age =18

3. On HAART (Highly active anti-retroviral therapy) for at least 24 months, on stable regimen for at least 6 months prior to study entry. HAART is defined as a combination of two (2) classes dose regimen of approved ARV (antiretroviral)

4. CD4+ cell counts = 101 and < 350 cells/µL measured on at least two (2) measurements (including the screening value) within the previous 12 months prior to study entry Note: a single isolated value of CD4+ = 350 during this period (12 months prior to study entry) will be allowed to participate if the previous and subsequent CD4+ count is in the range of = 101 and < 350 cells/µL

5. Plasma HIV RNA < 50 copies/mL since at least 18 months with at least two (2) measurements (including the screening value) within the previous 6 months prior study entry Note: patients with single blip of detectable viremia during this period (6 months prior to study entry) will be allowed to participate if the prior and subsequent plasma HIV RNA levels are < 50 copies/mL

6. Adequate bone marrow, hepatic and renal function as follows:

• Hemoglobin = 10 g/dl

• Neutrophils = 1,000/µL

• Platelets = 100,000/µL

• AST, ALT, or Alk. Phosph. = 2.5 x ULN

• Total Bilirubin = 1.5 x ULN (or = 5 x ULN if the patient is treated by atazanavir or by indinavir, and if the increase is due to unconjugated bilirubin and if ALT and AST are normal)

• Lipase = 2 x ULN

• PT/PTT = 1.5 x ULN

• Estimated glomerular filtration = 60 ml/min (according to MDRD formula)

7. Normal blood Thyroid-Stimulating Hormone (TSH)

8. Ability to understand and sign informed consent

Exclusion Criteria:

1. AIDS-defining illness (category C) diagnosed within the last 12 months prior to study entry

2. History of HIV related encephalopathy

3. Active opportunistic infection including active tuberculosis

4. Previous treatment with IL-2 or IL-7 at any time prior to study entry

5. Any planned or probable modification of the anti-retroviral treatment during the first year or the first two cycles of CYT107 Note: in case of product shortage and in absence of viral mutation suspicion or viral blip, a modification of ARV will not be an exclusion criterion

6. Poor compliance on HAART or any other chronic treatment that in the opinion of the investigator will interfere with protocol participation

7. Previous treatment with immuno-modulatory agents such as, systemic corticosteroids, growth factors, immunosuppressive drugs, HIV vaccine, or anti-cancer treatment or hydroxyurea within 3 months prior to study entry

8. Any history of malignancy (except basal carcinoma of the skin) including any hematologic malignancy or AIDS defining malignancy, such as lymphoproliferative disorder or Kaposi's sarcoma Note: Patients with Kaposi's sarcoma limited to the skin that had disappeared while on HAART therapy, and without requiring any other systemic therapy 1 year prior to study entry, will be eligible.

9. Any history of severe auto-immune disease requiring systemic treatment or hospitalization, or any active auto-immune disease requiring treatment (including multiple sclerosis)

10. History of splenectomy

11. Any hematologic disease associated with hypersplenism, such as thalassemia, hereditary spherocytosis, Gaucher's Disease, and autoimmune hemolytic anemia

12. Chronic hepatitis B or C

13. HIV-2, HTLV-1 or HTLV-2 seropositivity

14. Cirrhosis of any origin, and alcoholic or non alcoholic steato-hepatitis, either proven histologically or suspected

15. Hypertension with a resting systolic blood pressure > 140 or a resting diastolic blood pressure > 90 mm despite adequate antihypertensive treatment

16. Any cardiac, pulmonary, thyroid, renal, hepatic, gastrointestinal, neurological (central or peripheral) disease requiring therapy and considered as significant by the investigator or a severe disorder of hemostasis

17. Any serious illness requiring systemic treatment and/or hospitalization until the patient either completes therapy or is clinically stable on therapy, in the opinion of the principal investigator, for at least 30 days prior to study entry

18. Pregnant or lactating women. Women of childbearing potential must have a negative serum or urine pregnancy test at study entry

19. Refusal or inability to practice contraception regardless of the gender of the patient

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV

Intervention

Drug:
• CYT107
repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months

Locations

Country	Name	City	State
Italy	San Raffaele Scientific Institute	Milano
South Africa	Helen Joseph Hospital-Themba Lethu Clinic	Johannesbourg
Switzerland	University of Zurich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
Cytheris SA

Countries where clinical trial is conducted

Italy,  South Africa,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To study the biological activity and safety of repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months.		24 months	Yes
Secondary	To characterize CYT107 Pharmacokinetics (PK) / Pharmacodynamics (PD)		24 months	No
Secondary	To characterize the key immuno-pharmacological effects		24 months	No
Secondary	To assess CYT107 effect on HIV-induced chronic systemic immune hyper-activation and its consequences		24 months	No